Login to Your Account

ODAC In Favor Of Safety Trials For Amgen, J&J EPO Products

By Kim Coghill

Wednesday, May 5, 2004
GAITHERSBURG, Md. - The Oncologic Drugs Advisory Committee generally agreed that it is reasonable to ask makers of Aranesp and Procrit to conduct placebo-controlled trials to assess possible adverse events. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription